Oncology Based In-Vivo Cro Industry

Summary:

• The global oncology based in-vivo CRO market size reached USD 1.2 Billion in 2023.
• The market is expected to reach USD 2.3 Billion by 2032, exhibiting a growth rate (CAGR) of 6.9% during 2024-2032.
• North America leads the market, accounting for the largest oncology based in-vivo cro market share.
• Solid tumors accounts for the majority of the market share in the indication segment due to their widespread prevalence.
• Patient derived xenograft (PDX) model holds the largest share in the oncology based in-vivo cro industry.
• Based on the application, the market has been divided into hospitals and rehabilitation centers.
• The rising prevalence of cancer is a primary driver of the oncology based in-vivo cro market.
• Advancement of technology in in-vivo models is reshaping the oncology based in-vivo cro market.

Industry Trends and Drivers:

• Growing prevalence of cancer:

The rising incidence of cancer globally is a primary factor driving the oncology-based in-vivo contract research organization (CRO) market. As cancer cases increase, there is a growing demand for advanced research and preclinical studies to develop effective therapies. In-vivo CROs play a crucial role in this process by conducting animal model studies to understand cancer biology and evaluate the efficacy of new drugs. Pharmaceutical companies and research institutions increasingly rely on CROs to accelerate drug discovery and development due to their expertise and resources. The need for personalized medicine and targeted therapies in oncology also amplifies the demand for in-vivo CRO services, which are instrumental in identifying and testing specific treatment pathways. As cancer becomes a more prominent global health concern, the oncology-based in-vivo CRO market is expanding to meet the growing research and development needs.

• Rising pharmaceutical research activities:

The growing trend of outsourcing research and development activities in the pharmaceutical industry is driving the oncology-based in-vivo CRO market. Developing cancer therapies requires significant investment in infrastructure, specialized expertise, and regulatory compliance, which can be challenging for companies to manage in-house. As a result, many pharmaceutical and biotech firms are turning to CROs for preclinical oncology studies. CROs provide access to advanced research facilities, experienced personnel, and established protocols, helping companies reduce costs and streamline the drug development process. By outsourcing in-vivo studies to specialized CROs, pharmaceutical companies can focus on their core competencies while ensuring that their oncology pipelines progress efficiently. This trend is further fueled by the need for faster time-to-market for new cancer therapies, making in-vivo CRO services essential to the overall R&D strategy.

• Technological advancements:

The advancement of technology in in-vivo models is a significant factor propelling the oncology-based in-vivo CRO market. Innovations in genetic engineering, imaging techniques, and biomarker identification have improved the accuracy and efficiency of in-vivo studies. These advancements enable CROs to create more precise animal models that mimic human cancers, facilitating better predictions of how treatments will perform in human clinical trials. For instance, genetically modified mice or patient-derived xenograft (PDX) models allow for more realistic cancer studies, providing crucial insights into tumor growth, metastasis, and drug resistance. Additionally, advancements in non-invasive imaging technologies help researchers monitor tumor progression in real-time, reducing the need for invasive procedures and improving the quality of data collected. These technological improvements have made in-vivo CRO services indispensable for pharmaceutical companies focused on developing innovative cancer therapies.

For an in-depth analysis, you can request a sample copy of the report: https://www.imarcgroup.com/oncology-based-in-vivo-cro-market/requestsample

Oncology Based In-Vivo Cro Market Report Segmentation:

Breakup By Indication:

• Blood Cancer
• Solid Tumors
• Others

Solid tumors account for the majority of shares as they are more prevalent and require proper treatment.

Breakup By Model:

• Syngeneic
• Xenograft
• Patient Derived Xenograft (PDX)
• Others

Patient derived xenograft (PDX) model dominates the market as it can mimic human tumor biology and heterogeneity.

Breakup By Application:

• Hospitals
• Rehabilitation Centers

Based on the application, the market has been divided into hospitals and rehabilitation centers.

Breakup By Region:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America holds the leading position owing to a large market for oncology based in-vivo cro driven by technological advancements and developing healthcare infrastructure.

Top Oncology Based In-Vivo Cro Market Leaders:

• Champions Oncology Inc.
• Charles River Laboratories International Inc.
• Crown Bioscience Inc.
• Eurofins Scientific
• Evotec SE
• ICON Plc
• Labcorp Drug Development (Laboratory Corporation of America Holdings)
• Living Tumor Laboratory
• Taconic Biosciences Inc.
• The Jackson Laboratory
• WuXi AppTec
• Xentech

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.